Frederick T. Chin, Ph.D.
Academic Appointments
- Assistant Professor (Research), Radiology - Diagnostic Radiology
Key Documents
Contact Information
- Academic Offices
Personal Information Email Tel (650) 725-4182Alternate Contact Donna Niernberger Administrative Associate Email Tel Work (650)736-0449
Professional Overview
Administrative Appointments
- Head, Cyclotron Radiochemistry, Stanford University School of Medicine, Department of Radiology, Stanford, CA USA (2005 - present)
- Member, Radioactive Drug Research Committee, Stanford University, Stanford, CA USA (2005 - present)
- Member, Administrative Panel on Radiological Safety, Stanford University, Stanford, CA USA (2009 - present)
- Member, Non-Human Use Radiation Safety Committee, Stanford University, Stanford, CA USA (2011 - present)
Honors and Awards
- NIH Fellow Award for Research Excellence, National Institutes of Health, Bethesda, MD USA (2003, 2004)
- NIH Intramural Research Fellowship, National Institutes of Health, Bethesda, MD USA (2002-2005)
- LBNL Research Fellowship, Lawrence Berkeley National Laboratory, Berkeley, CA USA (2001-2002)
- Physical Scientist Research Award, Indiana University School of Medicine, Department of Radiology, Indianapolis, IN USA (1998)
- "Excellence in Teaching" Award, Indiana University - Purdue University at Indianapolis, Indianapolis, IN USA (1998)
- Phi Beta Kappa, Indiana University, Bloomington, IN USA (1990)
Professional Education
| Ph.D.: | Purdue University, W. Lafayette, IN, Organic Chemistry/Radiochemistry (2000) |
| B.S. with Honors: | Indiana University, Bloomington, IN, Chemistry (1991) |
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
Our group's primary objectives are:
1) Novel radioligand and radiotracer development.
We will develop novel PET (Positron Emission Tomography) imaging agents with MIPS and Stanford faculty as well as other outside collaborations including academia and pharmaceutical industry. Although my personal research interests will be to discover and design of candidate probes that target molecular targets in the brain, our group focus will primarily be on cancer biology and gene therapy. In conjunction with our state-of-the-art imaging facility, promising candidates will be evaluated by PET imaging in small animals and primates. Successful radioligands and/or radiotracers will be extended towards future human clinical applications.
2) Designing new radiolabeling techniques and methodologies.
We will aim to design new radiolabeling techniques and methodologies that may have utility for future radiopharmaceutical development in our lab and the general radiochemistry community.
3) Radiochemistry production of routine clinical tracers.
Since we also have many interests with many Stanford faculty and outside collaborators, our efforts will also include the routine radiochemistry production of many existing radiotracers for human and non-human use. Our routine clinical tracers will be synthesized in custom-made or commercial synthetic modules (i.e. GE TRACERlab modules) housed in lead-shielded cells and be distributed manually or automatically (i.e. Comecer Dorothea) to our imagers.
Clinical Trials
- Recruiting Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
- Not Recruiting A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
- Not Recruiting Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
Publications
- 18F-Fluorobenzoate-Labeled Cystine Knot Peptides for PET Imaging of Integrin αvβ6. J Nucl Med. 2013
- No-carrier-added [18F]fluoroarenes from the radiofluorination of diaryl sulfoxides. Chem Commun (Camb). 2013; (21): 2151-3
- Synthesis of ligand-functionalized water-soluble [18F]YF3 nanoparticles for PET imaging. Nanoscale. 2013; (8): 3253-6
- Efficient method for site-specific 18F-labeling of biomolecules using the rapid condensation reaction between 2-cyanobenzothiazole and cysteine. Bioconjug Chem. 2012; (9): 1902-8
- First experience with clinical-grade ([18F]FPP(RGD₂): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol. 2012; (1): 88-95
- New positron emission tomography (PET) radioligand for imaging σ-1 receptors in living subjects. J Med Chem. 2012; (19): 8272-82
Help